Last updated on August 2019

Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)


Brief description of study

This is a randomised, double-blind, parallel group, placebo-controlled study designed to evaluate the efficacy and safety of a fixed 30 mg dose of benralizumab administered subcutaneously for patients with a history of asthma exacerbations and uncontrolled asthma receiving medium to high-dose inhaled corticosteroid plus long-acting 2-agonist (ICS-LABA) with or without oral corticosteroids and additional asthma controllers.

Detailed Study Description

Approximately 666 patients will be randomised. Patients will be stratified by country/region, age group (adult or adolescent), and peripheral blood eosinophil count at time of Visit 1 (<300 or 300 cells/L).All the patients will be randomised to either placebo or benralizumab (1:1 ratio) for a 48-weeks treatment, every 4 weeks for the first 3 doses and then every 8 weeks thereafter.

Clinical Study Identifier: NCT03186209

Find a site near you

Start Over

Research Site

Chongqing, China
  Connect »

Research Site

Guang Zhou, China
  Connect »

Research Site

Guangzhou, China
  Connect »

Research Site

Hang Zhou, China
  Connect »

Research Site

Zhanjiang, China
  Connect »

Research Site

Bucheon-si, Korea, Republic of
  Connect »

Research Site

Busan, Korea, Republic of
  Connect »

Research Site

Cheonan-si, Korea, Republic of
  Connect »

Research Site

Daejeon, Korea, Republic of
  Connect »

Research Site

Gwangju, Korea, Republic of
  Connect »

Research Site

Seongnam-si, Korea, Republic of
  Connect »

Research Site

Seoul, Korea, Republic of
  Connect »

Research Site

Suwon-si, Korea, Republic of
  Connect »

Research Site

Uijeongbu-si, Korea, Republic of
  Connect »

Research Site

Wonju-si, Korea, Republic of
  Connect »

Research Site

Iloilo City, Philippines
  Connect »

Research Site

Manila, Philippines
  Connect »